-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

Benzinga·07/01/2026 11:48:02
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $6 price target.